Cargando…
Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482666/ https://www.ncbi.nlm.nih.gov/pubmed/34587994 http://dx.doi.org/10.1186/s13045-021-01176-1 |
| _version_ | 1784576957326819328 |
|---|---|
| author | Yu, Zhaojin Liu, Wensi He, Ying Sun, Mingli Yu, Jiankun Jiao, Xue Han, Qiang Tang, Haichao Zhang, Bing Xian, Yunkai Qi, Jing Gong, Jing Xin, Wang Shi, Gang Shan, Fengping Zhang, Rui Li, Jianping Wei, Minjie |
| author_facet | Yu, Zhaojin Liu, Wensi He, Ying Sun, Mingli Yu, Jiankun Jiao, Xue Han, Qiang Tang, Haichao Zhang, Bing Xian, Yunkai Qi, Jing Gong, Jing Xin, Wang Shi, Gang Shan, Fengping Zhang, Rui Li, Jianping Wei, Minjie |
| author_sort | Yu, Zhaojin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8482666 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84826662021-10-04 Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine Yu, Zhaojin Liu, Wensi He, Ying Sun, Mingli Yu, Jiankun Jiao, Xue Han, Qiang Tang, Haichao Zhang, Bing Xian, Yunkai Qi, Jing Gong, Jing Xin, Wang Shi, Gang Shan, Fengping Zhang, Rui Li, Jianping Wei, Minjie J Hematol Oncol Correction BioMed Central 2021-09-29 /pmc/articles/PMC8482666/ /pubmed/34587994 http://dx.doi.org/10.1186/s13045-021-01176-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Yu, Zhaojin Liu, Wensi He, Ying Sun, Mingli Yu, Jiankun Jiao, Xue Han, Qiang Tang, Haichao Zhang, Bing Xian, Yunkai Qi, Jing Gong, Jing Xin, Wang Shi, Gang Shan, Fengping Zhang, Rui Li, Jianping Wei, Minjie Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine |
| title | Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine |
| title_full | Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine |
| title_fullStr | Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine |
| title_full_unstemmed | Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine |
| title_short | Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine |
| title_sort | correction to: hla-a2.1-restricted ecm1-derived epitope la through dc cross-activation priming cd8+ t and nk cells: a novel therapeutic tumour vaccine |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482666/ https://www.ncbi.nlm.nih.gov/pubmed/34587994 http://dx.doi.org/10.1186/s13045-021-01176-1 |
| work_keys_str_mv | AT yuzhaojin correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT liuwensi correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT heying correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT sunmingli correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT yujiankun correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT jiaoxue correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT hanqiang correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT tanghaichao correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT zhangbing correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT xianyunkai correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT qijing correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT gongjing correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT xinwang correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT shigang correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT shanfengping correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT zhangrui correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT lijianping correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine AT weiminjie correctiontohlaa21restrictedecm1derivedepitopelathroughdccrossactivationprimingcd8tandnkcellsanoveltherapeutictumourvaccine |